Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB751689 · 6 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| SB-751689 | DRUG | - |
| SB-751689 oral tablets (100 and 400 ng) | DRUG | - |
| Ketoconazole (NIZORAL) oral tablets (200 mg) | DRUG | - |
| SB-751689 oral tablets (400 mg) | DRUG | - |
| SB751689 | DRUG | - |
Inclusion Criteria: * Healthy adult males or females between the ages of 21 and 55, inclusive, will be eligible for the study. Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophorectomy ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
SB751689 is an investigational small molecule being developed for osteoporosis. It is a Phase 1 drug candidate studied in postmenopausal women and healthy volunteers. All six clinical trials for SB751689 have been completed, with a total enrollment of 113 participants. The drug is not approved and remains in clinical development.
SB751689 is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for osteoporosis. GSK has sponsored multiple completed trials evaluating the drug's safety, metabolism, and absorption in healthy volunteers and postmenopausal women.
SB751689 is in Phase 1 clinical development. All six trials for the drug have been completed, with no active trials currently ongoing. The drug is investigational and has not been approved for any use. It is being studied for the treatment of osteoporosis in postmenopausal women and healthy volunteers.
SB751689 has been studied in six completed Phase 1 trials, including NCT00388596, NCT00499928, NCT00540878, and NCT00554255. These trials evaluated the drug's interactions, metabolism, excretion, and absorption in healthy postmenopausal women and Japanese postmenopausal women. No active trials are currently listed for SB751689.
Yes, SB751689 and SB-751689 refer to the same investigational drug. The drug is being developed by GSK plc for osteoporosis. It has been studied in Phase 1 clinical trials, including studies with healthy postmenopausal women and Japanese postmenopausal women. The drug is not approved and remains in clinical development.